Cook Launches 140-mm Zilver PTX Stent in Europe
March 1, 2017—Cook Medical announced the launch of the 140-mm Zilver PTX paclitaxel-eluting stent in Europe. The addition to the company's Zilver PTX product portfolio allows for the treatment of longer lesions with just one stent. The device is deployed via a thumbwheel delivery system.
The Zilver PTX drug-eluting stent is indicated for the treatment of superficial femoral artery disease and has been demonstrated to reduce restenosis and reinterventions by approximately 50% over 5 years compared to Cook's Zilver bare-metal stents and percutaneous transluminal angioplasty.
In March 2016, the 5-year results of the Zilver PTX randomized controlled trial were published by Michael D. Dake, MD, et al online ahead of print in Circulation. The clinical trial confirmed long-term patency for patients treated with the Zilver PTX for peripheral artery disease in femoropopliteal arteries.